Jubilant Pharmova has announced the appointment of Daniel J. O’Connor as CEO of its proprietary novel drugs business, Jubilant Therapeutics Inc.  

O’Connor brings more than three decades of leadership experience in biotechnology and oncology, with a proven record of creating value around differentiated, IP-rich platforms. Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation, culminating in its successful acquisition.   

Earlier in his career, O’Connor played a key role at ImClone Systems, contributing to the clinical development, launch and commercialisation of a major oncology therapy while navigating complex intellectual property and inventorship challenges. He also served as CEO of Advaxis, a NASDAQ-listed immuno-oncology company, where he led its transformation into a late-stage clinical enterprise, secured substantial growth capital, and forged strategic collaborations with leading pharmaceutical partners.

O’Connor said, “I am honoured to lead Jubilant Therapeutics, a company dedicated to driving breakthrough innovation for cancers that are difficult to treat. I look forward to collaborating closely with our talented team to advance our mission and deliver meaningful value to patients, partners, and stakeholders alike.”

Shyam S. Bhartia, Chairman and Hari S. Bhartia, Co-Chairman, Jubilant Pharmova, welcomed Dan as the company advances its mission of “building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications.”

Headquartered in Pennsylvania, Jubilant Therapeutics is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients.